Jump to content

PD l

Lin wilki

Recommended Posts


These days almost every lung cancer patient has a lab test to determine treatment eligibility for both targeted therapy and immunotherapy. For the former, an alphabet soup's worth of letters is used to categorize the biomarkers such as: ALK, EGFR, ROS1, BRAF and NTKR. These are only present in small percentages of folks who have the lung cancer subtype of adenocarcinoma.

The lab test for immunotherapy checks for two proteins: PD-1 on T cells, and PD-L1 on healthy cells and or cancer cells. Here is a quote from the LUNGevity Lung Cancer 101 site that explains the interaction of PD-1 and PD-L1: "When the PD-1 on T cells attaches to the PD-L1 on other cells, the T cells know not to attack those other cells. Cancer cells can thus evade detection by T cells, with the result that the T cells's immune response is lessened at a time when it should be active. This allows cancer cells to thrive." Immunotherapy as a treatment can work on both adenocarcinoma and squamous cell.  There is a study ongoing to check its effectiveness with small cell lung cancer.

Your next question might be what is a good PD-1 or PD-L1 number? The number is expressed as a percentage and the percentage varies from 1% or less to 99% and the level of expression suggest which of the immunotherapy drugs that may be effective.  

Stay the course.


Link to comment
Share on other sites

Thanks. I am in a clinical trial with 2 types of immunotherapy.  I know I did not have EFGR or ALK mutations which made me eligible for the trial.  Im asking my doc about my PDL

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.